{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bass AR"],"funding":["Abbott Laboratories","Weill Cornell Clinical &amp; Translational Science Center","Pfizer Foundation"],"pagination":["67-76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5786589"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["<h4>Background</h4>Orthopedic patients are at risk for adverse postoperative cardiovascular outcomes.<h4>Questions/purposes</h4>This pilot randomized controlled trial (RCT) of atorvastatin vs. placebo in orthopedic surgery patients was performed in order to assess: (1) the prevalence of perioperative myocardial injury; (2) the effect of atorvastatin on perioperative inflammation; and (3) the feasibility of performing a large RCT of statin therapy in orthopedic patients.<h4>Methods</h4>Hip fracture (hip Fx) and total hip and knee replacement (THR and TKR) patients were randomized 1:1 to atorvastatin 40 mg daily vs. placebo, starting preoperatively and continuing until postoperative day (POD) 45. High-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hs-CRP), and"],"journal":["HSS journal : the musculoskeletal journal of Hospital for Special Surgery"],"pubmed_title":["Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients."],"pmcid":["PMC5786589"],"funding_grant_id":["UL1TR000457-06"],"pubmed_authors":["Valle AGD","Eby C","Merritt K","Stevens SM","Moskowitz G","Flores E","Szymonifka JD","Rondina MT","Bogardus M","Gage BF","Scott MG","Bass AR","Woller SC"],"additional_accession":[]},"is_claimable":false,"name":"Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients.","description":"<h4>Background</h4>Orthopedic patients are at risk for adverse postoperative cardiovascular outcomes.<h4>Questions/purposes</h4>This pilot randomized controlled trial (RCT) of atorvastatin vs. placebo in orthopedic surgery patients was performed in order to assess: (1) the prevalence of perioperative myocardial injury; (2) the effect of atorvastatin on perioperative inflammation; and (3) the feasibility of performing a large RCT of statin therapy in orthopedic patients.<h4>Methods</h4>Hip fracture (hip Fx) and total hip and knee replacement (THR and TKR) patients were randomized 1:1 to atorvastatin 40 mg daily vs. placebo, starting preoperatively and continuing until postoperative day (POD) 45. High-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hs-CRP), and","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Feb","modification":"2026-05-05T04:36:09.5Z","creation":"2019-03-26T22:50:03Z"},"accession":"S-EPMC5786589","cross_references":{"pubmed":["29398998"],"doi":["10.1007/s11420-017-9577-1"]}}